Mometasone furoate detailed information
You don't need to be Editor-In-Chief to add or edit content to WikiDoc. You can begin to add to or edit text on this WikiDoc page by clicking on the edit button at the top of this page. Next enter or edit the information that you would like to appear here. Once you are done editing, scroll down and click the Save page button at the bottom of the page.
| |
| Mometasone furoate detailed information
| |
| Systematic (IUPAC) name | |
| (9R,10S,11S,13S,14S,16R,17R)-9-chloro- 17-(2-chloroacetyl)-11-hydroxy-10,13,16- trimethyl- 3-oxo-6,7,8,9,10,11,12,13,14,15,16,17- dodecahydro-3H-cyclopenta[a]phenanthren- 17-yl furan-2-carboxylate | |
| Identifiers | |
| CAS number | 83919-23-7 as Furoate |
| ATC code | D07 D07XC03, R01AD09, R03BA07 |
| PubChem | |
| DrugBank | |
| Chemical data | |
| Formula | C22H28Cl2O4 for Mometasone C27H30O6Cl2 as Furoate |
| Mol. mass | 427.361 g/mol |
| Pharmacokinetic data | |
| Bioavailability | Nasal spray is virtually undetectable in plasma |
| Protein binding | 98% to 99% |
| Metabolism | hepatic |
| Half life | 5.8 hours |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status | |
| Routes | topical, nasal |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Phone:617-525-6884
Please Join in Editing This Page and Apply to be an Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [2] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.
Overview
Mometasone furoate (also referred to as Mometasone) is a moderately potent glucocorticoid steroid used in the treatment of inflammatory skin disorders (such as eczema and psoriasis), allergic rhinitis (such as hay fever), and asthma for patients unresponsive to less potent corticosteroids. In terms of steroid strength, it is more potent than hydrocortisone, and less potent than dexamethasone.
Schering-Plough markets the medication under the following brand names; Elocon (Elocom) as a cream or ointment for skin conditions, Nasonex as a nasal spray for upper respiratory conditions, Asmanex Twisthaler as a dry powder inhaler (DPI) for lower respiratory conditions.
External links
Decongestants and other nasal preparations (R01) | |
|---|---|
| Topical: sympathomimetics, plain | Cyclopentamine - Ephedrine - Phenylephrine - Oxymetazoline - Tetryzoline - Xylometazoline - Naphazoline - Tramazoline - Metizoline - Tuaminoheptane - Fenoxazoline - Tymazoline - Epinephrine |
| Topical: antiallergic agents, excluding corticosteroids | Cromoglicic acid - Levocabastine - Azelastine - Antazoline - Spaglumic acid - Thonzylamine - Nedocromil - Olopatadine |
| Topical: corticosteroids | Beclometasone - Prednisolone - Dexamethasone - Flunisolide - Budesonide - Betamethasone - Tixocortol - Fluticasone - Mometasone furoate - Triamcinolone - Ciclesonide |
| Topical: other nasal preparations | Calcium hexamine thiocyanate - Retinol - Ipratropium bromide - Ritiometan - Mupirocin - Hexamidine - Framycetin |
| Systemic use: Sympathomimetics | Phenylpropanolamine - Pseudoephedrine - Phenylephrine |
Acknowledgement and Attribution Regarding Sources of Content
Some of the initial content on this page may be incorporated in part from copyleft sources in the public domain including wikis such as Wikipedia and AskDrWiki. Drug information for patients came from the The National Library of Medicine. Infectious disease information may have come from the Centers for Disease Control (CDC). Differential Diagnoses are drawn from clinicians as well as an amalgamation of 3 sources: 1.The Disease Database; 2. Kahan, Scott, Smith, Ellen G. In A Page: Signs and Symptoms. Malden, Massachusetts: Blackwell Publishing, 2004:3; 3. Sailer, Christian, Wasner, Susanne. Differential Diagnosis Pocket. Hermosa Beach, CA: Borm Bruckmeir Publishing LLC, 2002:7 .
